Woman walking again after bottle kicking trampling
Alexie Winship said she was among spectators watching the Hallaton bottle kicking in Leicestershire event last month when she was caught up in a scrum of participants.
The 24-year-old was taken to hospital where she was found to have suffered a neurological injury and a bleed on her spine, which left her without most feeling below her waist.
However, Ms Winship, from Market Harborough, Leicestershire, has told the BBC she is now continuing her recovery at home after two weeks in hospital.
Bottle kicking is an event where players attempt to wrestle wood kegs through a field to win.
Ms Winship said the action surged towards her, causing her to be pushed to the ground, kicked in the head and knocked unconscious.
She was taken first to the Leicester Royal Infirmary, then a week later to St Luke's Hospital in Market Harborough, before being discharged.
"I feel so lucky to be alive, it could have been so much worse," Ms Winship said.
She added that she was having physio to help her recovery.
Ms Winship said: "I have good days and bad days.
"With the feeling, it comes and it goes, it just depends on the day really. I am back at the gym now.
"But I find if I overdo it, that's when the side effects come into play.
"I do get really tired quite quickly now and standing up for lengthy periods of time puts a bit of strain on my back."
Recalling coming round in hospital, Ms Winship said she questioned whether she would ever walk again.
"I was just thinking, why has this happened to me?"
"I remember thinking, 'I hate this, I hate not being able to walk.'
"It was really frustrating," she said.
Bottle kicking takes place in a field between neighbouring villages Hallaton and Medbourne. It has few rules, but is won when players are able to carry two of three barrels across a stream back to their village.
Two of the "bottles" contain beer, while one is completely wooden - painted red and white - and is referred to as the dummy.
Organisers have said local legend suggested the event, preceded by a procession through Hallaton in which hare pies are scattered, can trace its roots back 2,000 years.
Ms Winship said she was an active, fit and healthy person who had been training to run a half-marathon before she was injured.
She said she aimed to run the 2026 London Marathon and has used the race as a target in her recovery.
After this year's event, Phil Allan, chairman of the bottle kicking organising committee, said he wished Ms Winship a "full recovery".
He added people were warned well in advance of the risks of entering the field of play.
"We don't want anyone to get hurt but you do get the odd injury - it's an age-old problem," Mr Allan said.
"We've looked at all sorts of things but you can't marshal it. It's an unpredictable event.
"We put posters up around the field telling people they enter at their own risk so they are warned. And we pay for ambulances and paramedics to attend in case anyone does get hurt."
Follow BBC Leicester on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
'Bottle kicking trampling left me unable to walk'
Villages slug it out in bottle kicking battle
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 days ago
- Medscape
Myeloma Expert: Is Early Immunotherapy a Game Changer?
Sagar Lonial, MD, is an internationally recognized leader in multiple myeloma research who has led landmark studies on the genetic diversity of the disease, participated in practice-changing trials, and spearheaded real-world data collection. But his focus on myeloma happened mostly by chance. Sagar Lonial, MD In 2001, Lonial was a junior faculty member at Winship Cancer Institute of Emory University, in Atlanta. He was becoming increasingly frustrated with a lack of advances in his area of focus — leukemia and allogeneic transplant — when he bumped into Ken Anderson, MD, in the hallway at the American Society of Hematology (ASH) annual meeting. 'I just happened to run into Ken Anderson at ASH, who said, 'Where are you going?' I said, 'I'm going to a leukemia session,' and he said, 'Why? Come follow me,'' recalls Lonial, who currently serves as the chief medical officer at Winship Cancer Institute and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine. Anderson, who was already a leader in the myeloma field, brought him to an investigator's meeting about bortezomib, a novel agent for myeloma. That chance encounter, and the collaboration and mentorship from Anderson that followed, helped Lonial build Emory's myeloma program into an internationally recognized leader in the field. 'I met Sagar over 25 years ago and at that time recognized what a rising star he was and encouraged him to pursue studies and clinical trials in multiple myeloma,' said Anderson, director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. 'This is now 25 years later, and Sagar has succeeded beyond belief. He's grown the multiple myeloma center at Emory Winship Cancer Institute into a world-class, leading research and clinical care center of excellence in the world.' The experience of changing his research focus from leukemia to myeloma is why Lonial advises junior faculty to avoid narrowing their focus for the first few years in academia. 'Don't say no to anything the first 4 years because you never know what opportunity is going to take you to where you are today,' Lonial said. 'Being open to change, being open to new ideas, doing something you never thought you'd be able to do, that challenge is what keeps you fresh.' Following the Science From the start, Lonial has been following the science. He was in high school when the identification of the RAS oncogene and its potential in cancer therapeutics inspired him to become an oncologist. He started working in the leukemia lab at Johns Hopkins during his freshman year as an undergraduate and was soon helping to design experiments on the newly cloned granulocyte- and granulocyte-macrophage colony-stimulating factor. In that lab, he met one of his first mentors, Judy Karp, MD, now his friend and collaborator for 30 years. 'Her commitment to the science and clinical trials is probably what got me started,' Lonial said. Lonial returned home to Kentucky to attend the University of Louisville School of Medicine, where he met his future wife — his assigned lab partner — on the first day of medical school. Already then, he had an interest in translational research and started working with an oncologist at Louisville on research projects. Lonial went on to residency at Baylor College of Medicine in Houston, where he worked closely with the transplant specialist, Phil McCarthy, MD, who is now at Roswell Park in Buffalo, New York. When it came time to start his fellowship, Lonial chose Emory, in part for the chance to work with some faculty members he had known from his time at Johns Hopkins who had moved to Emory. But by the time he arrived in Atlanta, that group had left. There was big faculty turnover then, and the department was in disarray. Nevertheless, Lonial said it ended up being an opportunity for him. 'There weren't a lot of people blocking me to do what I wanted to do,' he said. 'If you have good ideas and you have good external support, things just sort of fell into place, and I was able to write a couple of protocols and do some things as a fellow that I don't think I would have been able to do [otherwise].' After switching his focus to myeloma research, Lonial quickly made his mark on the evolving field. He has conducted laboratory work evaluating the impact of purified dendritic cell subsets on immune responses against antigens and has conducted several trials assessing the role of cytokines on dendritic cell content and immune recovery after transplant. Over the years, he's led trials for multiple novel agents that have gone on to become standard of care in myeloma, from immunomodulatory drugs (IMiDs) and proteasome inhibitors to monoclonal antibodies. More recently, he has investigated the synergistic inhibition of the PI3K/Akt pathway and the role of 14-3-3 in proteasome function. In June 2025, Lonial received the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation for his significant contributions in the field of myeloma research. Evolving the Myeloma Field Over the past 25 years, Lonial has had a front-row seat on advances in the myeloma treatment landscape. 'Back then, it was melphalan and thalidomide. That's pretty much all we had,' Lonial said. Early on, Lonial said that he and his colleagues at Emory were 'big believers' in maximizing early responses by consolidating with a transplant and using maintenance therapy to keep patients under control. But the emergence of monoclonal antibodies, proteasome inhibitors, and second-generation IMiDs allowed them to change the treatment paradigm and begin to achieve complete remissions. Lonial recalls that Emory was ahead of the curve on the concept of using combination therapy in myeloma, rolling it out before phase 3 trials results made it standard of care. That allowed them to build a real-world dataset of patient outcomes showing that the approach worked and to achieve 'unprecedented durations of remission,' Lonial said. 'As we develop new molecules, we further refine the model, highlighting the idea of combining therapies as ultimately the best way to kill myeloma,' he said. Next, Lonial said he's excited to move that concept forward with immunotherapies. He is currently working with colleagues on designing a trial to assess a concept called 'total immune therapy' that would give patients with newly diagnosed myeloma treatment for every immune target within the first 2 years of treatment and then stop therapy, with the idea being to never let myeloma develop resistance. 'This idea of sort of cycling through and trying to really eliminate every subclone is what we're proposing for the next trial from us,' Lonial said. Rowing in the Same Direction Lonial splits his time among his research, administrative, and clinical responsibilities, but he sees teamwork as important to making all those roles work. Lonial is in the clinic once a week, so he relies on a team of advanced practice providers to be the 'eyes and ears' of the program and manage patients throughout the week. He takes a similar approach to managing the clinical trial load. The team of eight myeloma specialists divide the 25-30 open trials among themselves, but they generally enroll patients to all of them. 'We really want to make sure that we are pulling oars in the same direction,' Lonial said. Lonial tends to lead the early-phase trials of new drugs, giving junior faculty more opportunities to step up on the management of phase 2 and 3 trials, he said. He also works with the myeloma clinicians on having a unified practice approach. This type of team approach allowed the group to develop large, real-world datasets comparing RVD (lenalidomide, bortezomib, dexamethasone) with dara-RVD (daratumumab + RVD) in clinical practice. This unified practice approach, spearheaded by Lonial, has had a significant impact on the treatment of patients with myeloma, said Larry Boise, PhD, a professor of hematology and medical oncology at Emory, who has worked with Lonial for the past 16 years. 'He is all about team,' Boise said. 'Even though he's obviously highly accomplished at what he does, and has been recognized for that, he is very clear that he believes that his success has been because of the culture and environment here at Emory in the myeloma program. What he won't say is that he's the one who created it. He's the one who created that culture, and everyone has bought in because everyone gets their fair share of credit. He takes very little.' Challenges in Oncology Lonial sees his connection with patients as the most fulfilling part of his job, but he recognizes that it gets harder for physicians to build those relationships while also needing to fulfill requirements related to electronic medical records and patient volume. 'That's the real challenge that I see in medicine today,' he said. The other challenge for the field is creating greater access for patients to the full spectrum of advances in oncology. 'We have all these great new drugs — CAR [chimeric antigen receptor] T cells and bispecifics — they are going to be in more than hematologic malignancies; they are going to be in solid tumors. But the ability for patients in underserved areas to get them is a real challenge,' Lonial said. 'Figuring out how we make that access a little bit more democratic, I think, is going to ultimately be the social challenge that we as oncologists need to help deliver.'
Business Insider
4 days ago
- Business Insider
Aid cuts from the United States could advance terrorism in Nigeria
Aid agencies have warned that aid cuts from the United States to Nigeria could push more people into the hands of terrorist organizations in the Northern region of Nigeria. Aid agencies warn cuts to U.S. assistance in Nigeria may increase terrorism recruitment. The United Nations' WFP reduced rations following a funding decrease from the U.S. President Trump's America First policy impacted global humanitarian aid funding. In recent months, the United Nations' World Food Programme has trimmed down rations to Nigeria owing to a drop in funding from the United States. "It will be much easier for militants to lure youths to join them and spiral insecurity across the whole region," Trust Mlambo, head of operations in the area for WFP, told the BBC. Since assuming office, U.S. President Donald Trump has embarked on an aggressive campaign to cut wasteful spending, in what he described as an America First policy. The initiative has had a negative impact on humanitarian support for destitute and war-torn nations. On January 20, 2025, an executive order put a 90-day hold on all US foreign development assistance, leading to the widespread suspension of aid programs. Till today, the United States still insists on drastically reducing the amount of aid sent to other countries. In keeping with President Donald Trump's America First idea, the US State Department admitted that certain changes have been made as a result of its recent restructuring of humanitarian aid programs. "The United States continues to be the most generous nation in the world, and we urge other nations to increase their humanitarian efforts," a senior State Department official stated. 80% of US government assistance to the WFP has not been impacted, as seen in a report by the BBC. This year, the WFP has already seen a rise in malnutrition rates in Nigeria due to a decrease in funding from all donors. The number of children suffering from the most severe and fatal kind of malnutrition more than doubled over the first half of the year, according to Médecins Sans Frontières (MSF). "Six-hundred-and-fifty-two children have already died in our facilities since the beginning of 2025 due to lack of timely access to care," the medical charity said.
New York Post
4 days ago
- New York Post
23-year-old who died of cancer after refusing chemo had ‘five coffee enemas a day'
A 23-year-old British woman who died after refusing conventional cancer treatment was allegedly undergoing 'five coffee enemas a day' under the care of her mother, a controversial health influencer. Paloma Shemirani's brother made the claim this week during an inquest into her death, which came seven months after doctors told the Cambridge graduate she had an 80% chance of surviving non-Hodgkin lymphoma with chemotherapy, according to the BBC. Instead, she pursued an unproven alternative cancer regimen promoted by her mother, Kate Shemirani, who claimed to have used it successfully in the past. 5 Paloma Shemirani was just 23 when she died of cancer from 2024. Kate Shemirani/Facebook Paloma died of a heart attack on July 24 last year, caused by an untreated tumor. In written statements before her death, she denied having cancer at all, calling the diagnosis an 'absurd fantasy, with no proof,' per the BBC. She also expressed fears that chemotherapy might leave her infertile. 'I do not want to undergo such a harsh treatment that could even kill me when there is a possibility this is not cancer,' she wrote. Her parents, Kate and Faramarz Shemirani, told the BBC they believe Paloma 'died as a result of medical interventions given without confirmed diagnosis or lawful consent.' The outlet has not been able to substantiate their claims. Paloma's brothers, Sebastian and Gabriel, have publicly blamed their mother for fostering her distrust in modern medicine. 5 She refused chemo and, led by her mother, reportedly followed an alternative approach that aims to 'detoxify' the body through a strict vegan diet, natural juices, supplements and frequent coffee enemas. 'My sister has passed away as a direct consequence of my mum's actions and beliefs and I don't want anyone else to go through the same pain or loss that I have,' Gabriel told the BBC. Growing up in the small Sussex town of Uckfield, Gabriel said the 'soundtrack' to their household included conspiracy theorist Alex Jones — with claims that the Sandy Hook school shooting was staged and that 9/11 'was an inside job.' Kate Shemirani's distrust of conventional medicine intensified after she was diagnosed with breast cancer in 2012, according to her sons. 5 In written statements before her death, Paloma described her mother as 'an extremely forceful advocate for natural health.' PA Images via Getty Images Though she underwent surgery to remove the tumor, she has publicly credited her recovery to Gerson therapy — an alternative approach that aims to 'detoxify' the body through a strict vegan diet, natural juices, supplements and frequent coffee enemas. The FDA has not approved Gerson therapy for treating cancer or any other condition. Major cancer organizations warn against its use, citing a lack of scientific evidence and the risk of serious side effects. Kate Shemirani, a prominent figure in alternative health circles, is a former nurse who lost her license after the UK's Nursing and Midwifery Council found she used her professional status to spread 'distorted propaganda' during the COVID-19 pandemic, according to The Mirror. 5 Gabriel Shemirani, Paloma's brother, has blamed his mother's belief in conspiracy theories for her death. AFP via Getty Images In a 2021 interview with Sky News, she claimed that 'no vaccine has ever been proven safe and no vaccine has ever been proven effective,' and said she had seen 'no evidence' to suggest 'a pandemic exists.' Later that year, during an anti-lockdown rally in London's Trafalgar Square, Kate compared healthcare workers administering COVID vaccines to Nazi war criminals and falsely claimed the virus was being spread by the 'downright deadly' shots. Following the rally, her son Sebastian called for her to be 'prosecuted under existing laws' for her comments. 5 Kate Shemirani had raised concerns to doctors about the cancer treatments they recommended her daughter undergo. Getty Images 'It's only a matter of time before … somebody acts on the bad advice that she's giving the country,' he told BBC Radio 4's 'Today,' adding that he is worried his mother is 'beyond help.' In written statements before her death, Paloma described her mother as 'an extremely forceful advocate for natural health' who was often 'misquoted,' according to the BBC. The ongoing inquest into Paloma's death is focused on whether the care she received was appropriate. Before she died, she expressed confidence in Gerson therapy, saying she was 'delighted' with the alternative treatment and 'sure' she would 'make a full recovery' if allowed to continue.
